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Introduction
Thanks to the improvement of therapeutic techniques,
the survival rate in patients with head and neck cancer
has gradually increased. Depending on the site and ex-
tent of the primary tumour and the status of the lymph
nodes, oral cancer may be a consequence due to radi-
ation therapy and chemotherapy. A wide range of
functions may be affected including speech, degluti-
tion, the management of oral secretions and mastica-
tion. The oral complications displayed by head and
neck cancer patients that undergo radiation therapy are
mucositis, bacterial, viral and/or fungal infections, sali-
vary gland disfunction, dysgeusia, swallowing, major
tooth decay, sore mouth, jaw stiffness, denture prob-
lems, smell voice quality and larynx swelling (1-5).
Indeed, due to the deleterious side effects of these
treatments, patients experience a significant drop in
their quality of working and social life (1, 6), which
can adversely complicate the subsequent rehabilita-
tion.
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SUMMARY
Purpose. This study was aimed at assessing the effectiveness and the importance of an oral hygiene (OH) protocol in
patients undergoing radiation therapy and chemotherapy after prosthesis rehabilitation, in order to reduce or minimize oral
complications.
Materials and methods. This study was carried out at the Department of Dental Science, at the University of Bari-Italy from
December 2012 to December 2015 on 34 selected patients with primary oral cancer undergoing chemotherapy and ra-
diotherapy after prosthesis rehabilitation. They were divided into 2 groups according to their age, sex and cancer ther-
apy. Seventeen patients were assigned to the control group and seventeen in the experimental one. In the experimental
group (Table 1), patients underwent an oral hygiene protocol whereas in the control group (Table 2) patients received the
usual care provided within  the clinical setting. All the patients gave written informed consent. It has been asked and ob-
tained the authorisation from the Ethics Committee of the Dental Science and Surgery Department.
Results. Results show that in patients undergoing the oral hygiene protocol, the complications and the risks of infection
and permanent dental problems have been minimized. Indeed, of the seventeen patients undergoing the OH protocol,
70% obtained positive results and were satisfied with the program outcome.
Conclusions. The role of the health care providers is essential to educate patients to adhere to the prescribed treatments
and reinforce their motivation in oral hygiene. The oral hygiene procedures prevent and ameliorate oral complications due
to the radiation therapy and chemotherapy.
Key words: oral cancer, oral hygiene protocol, chemotherapy, radiotherapy.
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Given that the oral health care in the supervision oral
health before, during, and after cancer therapy is nec-
essary to reduce the incidence and severity of oral
complications (1), the aim of this study was to high-
light the importance of oral hygiene and provide an
oral hygiene protocol for the oral management during
chemotherapy or radiation therapy.
Materials and methods
At the Dental Science and Surgery Department, at the
University of Bari-Italy from December 2012 to De-
cember 2015 34 patients with primary oral cancer un-
dergoing chemotherapy and radiotherapy after pros-
thesis rehabilitation were examined. To reduce the in-
creased risks of infection and permanent dental prob-
lems, an oral hygiene protocol was applied. They were
divided into 2 groups according to their age (average
60-70 years), sex (10 males, 7 females), type of can-
cer therapy (head and neck surgery, chemotherapy,
head and neck irradiation and blood and bone marrow
transplant). Seventeen patients were assigned to the
control group and 17 to the experimental one. In the
experimental group (Table 1), patients underwent an
oral hygiene protocol whereas patients in the control
group (Table 2) received the usual care provided with-
in the clinical setting. All the patients gave written in-
formed consent. It has been asked and obtained the
authorisation from the Ethics Committee of the Den-
tal Science and Surgery Department.
Oral complications can cause serious and disabling
problems in patients undergoing cancer therapy.
Therefore, it is important to develop a specific instru-
ment to measure oral mucosal changes during therapy.
The Oral Mucosa Rating Scale (OMRS) has an exam-
ination rating scale to quantify the type and severity of
clinically evident oral mucosal changes (atrophy, ery-
thema, ulceration, and pseudomembranous, hyperker-
atotic, lichenoid, and edematous changes), with a
scale ranging from 0 to 3 (normal to severe). Separate
visual analogue scales are obtained for dryness and
osteoradionecrosis. To measure the severity of
bleeding, it has been used the World Health
Organization (WHO) standardized grading scale
ranging from 0 to 4 (no bleeding to debilitating blood
loss).
Research have shown that fewer problems develop
when oral disease is eliminated, when an oral prophy-
laxis is performed prior to the initiation of chemother-
apy (7) and when excellent oral hygiene is maintained
throughout therapy.
Therefore, the oral hygiene protocol during chemo -
therapy and radiation therapy should include the fol-
lowing steps:
First appointment (2 weeks
before initiation radiations 
or chemotherapy)
• Medical history or anamnesis: patient’s cancer
diagnoses (disease and stage), past and planned
treatments, the patient’s oral health conditions and
current treatments and his haematological health
state with regard to the leukocyte and platelet count
(7, 8).
• Oral and clinical examination and radiographic
evaluation: dental formula, caries, mucositis and
dry mouth, plaque score and plaque index, bleeding
on probing, pockets and alveolar bone loss (Dental
Panoramic Tomography, DPT or Serigraphy) (9).
Preventive and therapeutic care: any periodontally
weak or mutilated tooth should be extracted. Ab-
scessed teeth should be extracted or treated endodon-
tically. All surgical procedures should be completed at
least 10-12 days prior to onset of neutropenia. Addi-
tional therapy like restoration of carious teeth, re-
placement of faulty restorations, removal or correc-
tion of ill-fitting partial or complete prosthesis should
be done. Dentures should be meticulously cleaned and
soaked daily in nystatin to obviate often unsuspected
source of fungi (7) as well as adequate time for wound
healing before the induction of radiations and che -
motherapy.
Conservative dentistry and extractions: at this stage,
conservative treatment may be carried out. Endodontic
therapy (10, 11) and extractions are not contraindicat-
ed, as long as the patient does not present signs and
symptoms of osteoradionecrosis and haematological
dysfunctions. Invasive therapies need antibiotic pro-
phylaxis, especially in patients with leucopenia (7, 12).
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Oral hygiene instruction and motivation: detailed oral
hygiene instructions on specific oral care practices
should be provided to ensure that patient fully under-
stand what is required and may carry out appropriate-
ly at home (9).
Impression taking for study models: preliminary gyp-
sum models should be prepared for each patient who
has experienced a surgical operation for the removal
of an oral neoplasia (3) in order to correct or minimize
maxillary defects. Disabilities created by surgery of
the hard or soft palate may cause problems: chewing
(mastication) may be difficult (13), particularly for the
patient without natural teeth. Because denture-bearing
tissue surfaces are lost, it is difficult for the denture to
seal completely around the edges, a key factor in hold-
ing it securely in place. Swallowing likely will be-
Table 1 - Group A: Patients undergoing the oral hygiene protocol.
Sex Age Oral health status Types of cancer Stage of Type of cancer therapy Evaluation of oral 
disease complications
m 67 partially edentulous oral cavity cancer: Stage II radiotherapy no oral
the alveolar ridge complications
m 73 edentulous oral cavity cancer: Stage III surgery and minor
the retromolar trigone postoperative radiation improvement
f 75 edentulous oral cavity cancer: Stage II surgery and no oral 
the hard palate radiotherapy complications
m 66 partially edentulous oral cavity cancer: Stage II radiotherapy no oral 
the buccal mucosa complications
m 71 partially edentulous oral cavity cancer: Stage I radiotherapy no oral 
the alveolar ridge complications
f 74 edentulous oral cavity cancer: Stage II surgery and minor improvement
the hard palate radiotherapy
f 65 partially edentulous nasal cavity and Stage II chemotherapy and no oral
paranasal sinuses radiotherapy complications
m 70 edentulous oral cavity cancer: Stage II surgery and no oral 
the hard palate radiotherapy complications
f 68 partially edentulous oral cavity cancer: Stage II radiotherapy minor improvement
the alveolar ridge
m 77 edentulous nasal cavity and Stage II chemotherapy and no oral 
paranasal sinuses radiotherapy complications
m 64 partially edentulous oral cavity cancer: Stage II radiotherapy minor improvement
the retromolar trigone
f 63 partially edentulous oral cavity cancer: Stage II radiotherapy no oral 
the buccal mucosa complications
m 72 edentulous oral cavity cancer: Stage III chemotherapy and minor
the hard palate marrow bone transplant improvement
m 70 partially edentulous nasal cavity and Stage II chemotherapy and no oral 
paranasal sinuses radiotherapy complications
f 63 partially edentulous oral cavity cancer: Stage II radiotherapy no oral 
the retromolar trigone complications
m 60 partially edentulous oral cavity cancer: Stage II radiotherapy no oral 
the alveolar ridge complications
f 78 edentulous nasal cavity and Stage II chemotherapy and no oral
paranasal sinuses radiotherapy complications
original research article
ORAL & Implantology  -  Vol. IX - Suppl. 1/2016 to N. 4/2016 93
Table 2 - Group B: Patients who do not follow the oral hygiene protocol.
Sex Age Oral health status Types of cancer Stage of Type of cancer therapy Evaluation of oral 
disease complications
m 66 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection
the alveolar ridge and xerostomia
f 68 edentulous oral cavity cancer: Stage III surgery and mucositis, infection 
the retromolar trigone postoperative radiation xerostomia and 
osteoradionecrosis
m 75 edentulous oral cavity cancer: Stage II surgery and radiotherapy mucositis, infection
the hard palate xerostomia and 
osteoradionecrosis
m 67 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection
the buccal mucosa and xerostomia
f 74 partially edentulous oral cavity cancer: Stage I radiotherapy mucositis, infection
the alveolar ridge and xerostomia
m 61 edentulous oral cavity cancer: Stage II surgery and radiotherapy mucositis, infection
the hard palate xerostomia and 
osteoradionecrosis
f 63 partially edentulous nasal cavity and Stage II chemotherapy and mucositis, infection, 
paranasal sinuses radiotherapy xerostomia and
bleeding
m 73 edentulous oral cavity cancer: Stage II surgery and radiotherapy mucositis, infection
the hard palate xerostomia and 
osteoradionecrosis
f 76 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection 
the alveolar ridge and xerostomia
m 68 edentulous nasal cavity and Stage II chemotherapy and mucositis, infection,
paranasal sinuses radiotherapy xerostomia and
bleeding
m 76 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection 
the retromolar trigone and xerostomia
f 78 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection 
the buccal mucosa and xerostomia
m 70 edentulous oral cavity cancer: Stage III chemotherapy and marrow mucositis, infection,
the hard palate bone transplant xerostomia and 
bleeding
f 72 partially edentulous nasal cavity and Stage II chemotherapy and mucositis, infection, 
paranasal sinuses radiotherapy xerostomia and 
bleeding
m 69 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection 
the retromolar trigone and xerostomia
m 65 partially edentulous oral cavity cancer: Stage II radiotherapy mucositis, infection 
the alveolar ridge and xerostomia
f 79 edentulous nasal cavity and Stage II chemotherapy and mucositis, infection, 
paranasal sinuses radiotherapy xerostomia and
bleeding
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come awkward, since food and liquid may be forced
up into the nasal cavity and out the nose. The nasal
mucous membranes become dried out (desiccated) by
abnormal exposure to the oral environment, causing
chronic irritation. Nasal and sinus secretions may col-
lect in the defect area. Facial disfigurement can result
from lack of midface bony support for the facial soft
tissues, or the necessary surgical damage to a branch
of the facial nerve. In some cases, extensive tumour
invasion requires surgical removal of the eye (14). To
remedy the surgical defect after surgical resection of
the hard or soft palate and improve patient’s quality of
life, a temporary prosthesis, known as an immediate
surgical obturator, is placed. During the healing peri-
od, this prosthesis is relined periodically to compen-
sate for tissue changes which occur as a normal part of
the healing process. When these tissues become well
healed and dimensionally stable (usually 3 to 4
months after surgery), the final prosthesis is made
(14). The goal of an obturator prostheses is to main-
tain the physical separation between the oral and nasal
cavities, thereby restoring speech and swallowing to
normal, and to provide support to the lip and cheek.
Inadequate retention of the obturator compromises
stability. The remaining teeth, therefore, become ex-
tremely valuable in providing support, retention, and
stability for these restorations. Immediate or early
coverage of a palatal defect with an obturator is im-
portant (14). An obturator is used to provide a matrix
upon which the surgical packing can be placed, mini-
mizes contamination of the wound in the immediate
postoperative period, and enables the patient to speak
and swallow effectively immediately after surgery. In
order to fabricate the prostheses, a stone model is
made of the maxillary arch and the anterior portion of
the soft palate. The obturator’s size is determined by
the surgical boundaries of the resection, as indicated
by the surgeon. In the patient who still has natural
teeth, those in the path of the surgical resection are re-
moved from the model. The obturator can now be
made before the surgery, using self-curing plastics,
and be ready for immediate insertion afterwards. If
necessary, this first obturator can be altered at surgery
by trimming its size, or by adding a temporary denture
reline material. After surgery, the prosthesis is wired
to remaining teeth, alveolar ridge, or other available
structures (14).
Dietary advice: a sugar-free diet reduce the risk of de-
veloping caries.
Second appointment 
(5-6 days after radiations or
chemotherapy)
Oral hygiene evaluation and motivation: by using a
plaque score or a plaque index and by checking de-
posits on teeth and for all kinds of prostheses.
Prescription of medicaments: preventive measures are
essential to minimize discomfort in patients undergo-
ing radiotherapy and chemotherapy. In patients who
suffer from mucositis, the interventions used to reduce
mucosal toxicity should include allopurinol, growth
factors and providing-based mouthwashes, hydrolytic
enzymes, amiphostine, sucralfate and antibiotics, hon-
ey, low-intensity laser, oral hygiene, analgesics and
anti-inflammatory drugs (15).
Oral management of the xerostomic patient includes
(16): plaque removal: tooth brushing; flossing; other
oral hygiene aids; remineralizing solutions (17): fluo-
ride and calcium/phosphates; topical high concentra-
tion fluorides; topical antimicrobial rinses (chlorhexi-
dine solutions/rinses; povidone iodine oral rinses;
tetracycline oral rinses). Sialogogues (pilocarpine; ce-
vimeline; bethanechol; antholetrithione).
Patients who develop osteoradionecrosis should be
comprehensively managed to include elimination of
trauma, avoidance of removable dental prosthesis if
the denture-bearing area is within the osteonecrotic
field, assurance of adequate nutritional intake, and
discontinuation of tobacco and alcohol use. Topical
antibiotics (e.g., tetracycline) or antiseptics (e.g.,
chlorhexidine) may contribute to wound resolution
(18, 19). Hyperbaric oxygen therapy (HBO) is also
suggested for the management of ORN, though it has
not been universally accepted. In cases presenting ear-
ly, 30 HBO dives to 2.4 atmospheres for 90 minutes
have been advocated. Good responders should contin-
ue to a total of 40 dives. Those planned for radical
surgery should have 20 dives preoperatively followed
by 10 dives post operatively (20). Radical surgery
may be required in severe cases of osteoradionecrosis
(20).
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Oral hygiene motivation reinforcement: patients
should be informed about their oral hygiene condition
and motivated/educated again if it was necessary. If
the patient’s oral hygiene is satisfactory, he will be en-
couraged to carry on. Considering the patient health
status, the practitioner should always be aware that he
is making a consistent effort. For this reason, his con-
dition has to be improved (21). Patients suffering from
xerostomia should be advocated to brush and floss
regularly and to use fluoride daily (22). It is recom-
mended to use a 0.4% stannous fluoride gel or a 1.1%
neutral sodium fluoride gel, preferably unflavoured. If
tooth decay continues, it is useful to apply the fluoride
tray method. 
It is possible to obtain a fluoride tray on a gypsum
model resulting from alginate impressions. The tray
margins may be smoothened with a fine bur for com-
posite (23).
Third/fourth appointment
(after 5-6 days)
Reassessment of oral hygiene and reinforcement of
oral hygiene motivation: all patients should be moni-
tored to check their periodontal hygiene and motivat-
ed once again (21) if necessary.
Following appointments (twice
a month)
Periodontal assessment and reinforcement of oral hy-
giene motivation: it is recommended to check the pa-
tient oral hygiene and correct his oral hygiene tech-
niques. It is suggested to check patients leukocyte and
platelet counts and in relation to these values therapy
might eventually be modified (3). Follow-up appoint-
ments are a good opportunity to substitute the condi-
tioning material used for the obturator. When oral hy-
giene is satisfactorily reached and maintained (it usu-
ally takes three months), follow-up visits may be car-
ried out on monthly appointments.
Follow-up (every 7-10 days)
Results
Results show that after the beginning of the oral hy-
giene protocol, the complications and the risks of in-
fection and permanent dental problems have been min-
imized. Indeed, among the 17 dental assisted-patients,
70% obtained positive results in relation to those who
received the common dental treatments. The oral cavi-
ty was free from sources of irritation and infections and
patients were satisfied with the program outcome.
Discussion
Orally side effects are a major source of illness in pa-
tients undergoing chemotherapy or radiotherapy. Com-
plications associated with chemo-radiotherapy can be
direct, caused by toxic action of treatment agents on the
proliferative mucosal lining of the mouth, or indirect.
Indeed, radiation of the head and neck may irreversibly
injure oral mucosa, muscles and bones that may result
in permanent xerostomia, rampant caries, soft tissue-
necrosis and osteoradionecrosis (ORN) of the jaw.
Chemotherapy side effects include: mucositis, mouth
bleeding, dry mouth, taste changes, mouth infections,
temporary hair loss, nausea with or without vomiting,
diarrhoea, weakness, vulnerability to infection, easy
bleeding and brushing, thrombocytopenia, leucopoenia,
neutropenia. Mucositis can occur in 40% of patients
treated with chemotherapy (5, 24) and its frequency de-
pends on the patient’s diagnosis, age, level of oral
health, and type, dose, and frequency of drug adminis-
tration (5). A significant discomfort and impairment of
the patient’s ability to eat and swallow is related to
acute severe OM which is also related to breaks in
treatment, the placement in feeding tubes and hospital-
ization (24).
Patients with xerostomia often complain of taste disor-
ders (dysgeusia), a painful tongue (glossodynia) and an
increased need to drink water, especially at night. Fur-
thermore, xerostomia can lead to increased dental
caries, parotid gland enlargement, inflammation and
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fissuring of the lips (cheilitis), inflammation or ulcers
of the tongue and buccal mucosa, oral candidiasis, sali-
vary gland infection (sialadenitis), halitosis and crack-
ing and fissuring of the oral mucosa (25, 26).
Some regeneration can occur several months after treat-
ment and the undesirable effects and symptoms of xe-
rostomia (dry mouth with discomfort, difficulty in
speech and swallowing) may be modified. However, re-
covery of adequate saliva for oral comfort and function
may take up to 12 months; in some cases the saliva re-
mains inadequate indefinitely, especially if the salivary
glands are directly irradiated. 
Osteoradionecrosis (ORN) is a complication that re-
sults from compromised vascularity following surgery
or from radiation-induced hypovascularity as well as
from cytotoxic effects on bone-forming cells and tissue,
hypocellularity, and hypoxia of affected bone (27).
With ageing and atherosclerotic changes there is an in-
creased dependence on blood supply from the attach-
ments. Besides, both the mandible and maxilla are the
only bones in the body that are exposed directly to the
external environment through the gingival attachment
of the teeth. Any breaches in the integrity of the tissues
result in healing with an increase in bone turnover. In
an irradiated field, minor insult such as periodontal dis-
ease, pulpal infections and procedures such as dental
extractions can result in delayed healing and in some
cases develop into osteoradionecrosis. Complications
associated with ORN include intractable pain, patho-
logic fractures, oral and cutaneous fistulas, and loss of
large areas of bone and soft tissue (27).
Only a minority of patients goes on to develop osteora-
dionecrosis following radiotherapy and this number is
thought to be falling thanks to a multidisciplinary col-
laboration along with developments in radiotherapy
and radiotherapy protocols and a better patient educa-
tion. Potentially riskful foci of oral disease should be
eliminated before radiation therapy begins.
Bleeding may occur during chemotherapy when anti-
cancer drugs affect the ability of blood to clot. Bleeding
may be mild or severe, especially at the gum line and
from ulcers in the mouth (28). When blood counts drop
below certain levels, blood may ooze from the gums.
Spontaneous gingival oozing may occur when platelet
counts diminish to less than 30.000/mm3, especially
when there is pre-existing gingivitis or periodontitis
(28). In case of pre-existing gingivitis or periodontis
gingival oozing can be induced even by normal function
or routine oral hygiene (brushing and flossing) (28).
On the basis of these considerations, it is essential that
a multidisciplinary approach is used for oral manage-
ment of the cancer patient before, during, and after can-
cer treatment. A multidisciplinary approach is suggest-
ed because the medical complexity of these patients af-
fects dental treatment planning, prioritization, and tim-
ing of dental care. Thus, a multidisciplinary doctors
team that includes oncologists, oncology nurses, and
dental generalists and specialists as well as octdental
hygienists, social workers, dieticians, and related health
professionals can often achieve highly effective pre-
ventive and therapeutic outcomes relative to oral com-
plications in such patients.
Conclusions
Patients who have been treated for oral neoplasia might
may minimize oral complications by changing their be-
haviours in their oral hygiene. Indeed, oral hygiene pro-
tocols may ameliorate and prevent oral complications
of cancer therapy and improve the quality of their life.
Thus, health care providers should continue to educate
patients and advise them to begin daily oral hygiene
home care routine as soon as possible and adhere to
prescribed oral hygiene procedures.
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